Chemotherapy for brain stem gliomas. 1999

C R Freeman, and G Perilongo
Departments of Oncology and Pediatrics, McGill University, 1650 Cedar Avenue, Room D5-400, Montreal, Quebec, Canada, H3G 1A4. cfreeman@is.muhc.mcgill.ca

Approximately 80% of tumors arising in the brain stem are diffuse intrinsic lesions. Patients typically present with a short duration of symptoms and signs with significant neurological impairment. Imaging findings are typical, and biopsy is not usually necessary to make a diagnosis. Standard treatment consists of radiotherapy alone. Although the majority of patients will show a significant improvement in neurological status following such treatment, the prognosis is very poor. The median time to disease progression is of the order of 5-6 months, the median survival time less than 1 year, and survival at 2 years and beyond, less than 10%. Over the last 10-15 years, numerous studies have been undertaken in an attempt to develop more effective treatment for children with diffuse intrinsic brain stem tumors. Using a hyperfractionated (twice-daily) schedule, doses of radiotherapy as high as 78 Gy have been given without success. Other approaches use chemotherapy combined with radiotherapy in a variety of different ways, including up-front, concurrent, and adjuvant chemotherapy, and high-dose chemotherapy with rescue. The results of these studies using chemotherapy, as well as other approaches using other systemic agents, are reviewed in detail.

UI MeSH Term Description Entries
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D020295 Brain Stem Neoplasms Benign and malignant intra-axial tumors of the MESENCEPHALON; PONS; or MEDULLA OBLONGATA of the BRAIN STEM. Primary and metastatic neoplasms may occur in this location. Clinical features include ATAXIA, cranial neuropathies (see CRANIAL NERVE DISEASES), NAUSEA, hemiparesis (see HEMIPLEGIA), and quadriparesis. Primary brain stem neoplasms are more frequent in children. Histologic subtypes include GLIOMA; HEMANGIOBLASTOMA; GANGLIOGLIOMA; and EPENDYMOMA. Medullary Neoplasms,Mesencephalic Neoplasms,Midbrain Neoplasms,Pontine Neoplasms,Brain Stem Neoplasms, Primary,Brain Stem Tumors,Brainstem Neoplasms,Brainstem Neoplasms, Primary,Brainstem Tumors,Medullary Tumors,Midbrain Tumors,Neoplasms, Brain Stem,Neoplasms, Brainstem,Neoplasms, Brainstem, Primary,Neoplasms, Medullary,Neoplasms, Mesencephalic,Neoplasms, Midbrain,Neoplasms, Pontine,Pontine Tumors,Primary Brain Stem Neoplasms,Primary Brainstem Neoplasms,Brain Stem Neoplasm,Brain Stem Tumor,Brainstem Neoplasm,Brainstem Neoplasm, Primary,Brainstem Tumor,Medullary Neoplasm,Medullary Tumor,Mesencephalic Neoplasm,Midbrain Neoplasm,Midbrain Tumor,Neoplasm, Brain Stem,Neoplasm, Brainstem,Neoplasm, Medullary,Neoplasm, Mesencephalic,Neoplasm, Midbrain,Neoplasm, Pontine,Neoplasm, Primary Brainstem,Neoplasms, Primary Brainstem,Pontine Neoplasm,Pontine Tumor,Primary Brainstem Neoplasm,Tumor, Brain Stem,Tumor, Medullary,Tumor, Midbrain,Tumor, Pontine,Tumors, Medullary,Tumors, Midbrain,Tumors, Pontine

Related Publications

C R Freeman, and G Perilongo
January 1985, Neurosurgery,
C R Freeman, and G Perilongo
December 2001, Current opinion in neurology,
C R Freeman, and G Perilongo
January 1993, Rays,
C R Freeman, and G Perilongo
June 1980, Cancer,
C R Freeman, and G Perilongo
October 1985, Cancer,
C R Freeman, and G Perilongo
January 1975, Veterinary pathology,
C R Freeman, and G Perilongo
January 1978, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
C R Freeman, and G Perilongo
May 1995, Current opinion in oncology,
C R Freeman, and G Perilongo
January 1998, Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery,
C R Freeman, and G Perilongo
January 1987, Pediatric neuroscience,
Copied contents to your clipboard!